Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes
Introduction
The lipoprotein status in patients with type 2 diabetes mellitus (DM) is generally characterized by hypertriglyceridemia, a low level of high density lipoprotein cholesterol (HDL-C), and a normal or mildly elevated low density lipoprotein cholesterol (LDL-C) [1]. It has been reported that in type 2 diabetes, LDL particles shift toward a smaller and denser form, which is more susceptible to oxidation, glycation and consequently, more atherogenic [2], [3].
Remnant-like lipoprotein particles cholesterol (RLP-C) and triglyceride (RLP-TG) levels in diabetics have been reported to be higher than in non-diabetics [4]. RLP-C has been recognized as an independent risk factor for coronary artery disease (CAD) in women by the Framingham Heart Study [5]. Although RLP-TG has not been recognized as an independent risk factor for CAD, RLP-TG levels in cases of sudden cardiac death were higher than individuals who died from sudden non-cardiac causes [6].
Bezafibrate and pravastatin are representatives of fibric acid derivatives and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors, respectively, and are frequently prescribed in Japan. However, which agent is more favorable for treating diabetic dyslipidemia is not known yet, because to our knowledge, there are only two reports which compared the effects of bezafibrate and pravastatin on lipoproteins in type 2 diabetics [7], [8]. Regarding the effects on RLP-C, only one study compared pravastatin with bezafibrate [8].
Recently, in clinical lipid research laboratories, the focus has been shifting from major lipoprotein classes to their subclasses. In this regard, the separation of LDL and HDL subclasses by ultracentrifugation (UC) based on hydrated density has been attempted [9]. However, lipoprotein analysis by UC is time-consuming and requires large amounts of test samples and special technical training. Recently, categorical classifications, not quantifications, of LDL and HDL subclasses by polyacrylamide gel electrophoresis (PAGE) have been widely attempted [10], [11]. The PAGE method gives the researchers information on particle size profiles, but cannot measure absolute cholesterol contents of subclasses. In view of this, Okazaki et al. have recently reported a high performance liquid chromatography (HPLC) method for lipoprotein subclass analysis [12]. The lipoprotein profiles obtained by the HPLC method can provide information on absolute cholesterol concentrations of both LDL and HDL subclasses simultaneously according to their particle sizes. The HPLC method is much less time-consuming and needs only a very small amount of test sample (5 μl of serum or plasma per measurement).
The objectives of this study were firstly to compare the effects of bezafibrate and pravastatin on lipoprotein metabolism including analyses of RLPs and lipoprotein subclasses in type 2 diabetics and secondly to evaluate the clinical usefulness of LDL and HDL subclasses as determined by the HPLC method.
Section snippets
Patients and study design
A total of 27 Japanese diabetic outpatients aged 51–80 year with hypercholesterolemia and/or hypertriglyceridemia according to the criteria of the Japan Atherosclerosis Society (total cholesterol level ≥5.69 mmol/l, triglyceride level ≥1.69 mmol/l) [13] were consecutively enrolled in this study. Diagnoses of hypercholesterolemia and hypertriglyceridemia were based on the mean value of at least three pre-treatment lipid measurements. A diagnosis of type 2 DM was made according to the World
Results
The baseline lipid profiles of two treatment groups were well matched and no carry-over effects were observed. Therefore, we conjugated the results of both treatment groups and made the subsequent analyses. Body mass indices and glycemic control levels of subjects did not change significantly during the study period. None of the patients discontinued the study and no serious adverse effects related to drugs were observed. Compliance with trial medication was over 90% during the study with no
Discussion
In this study, we compared the effects of bezafibrate and pravastatin on RLP-C, RLP-TG, and HPLC subclasses cholesterol of LDL and HDL in type 2 diabetic patients. To our knowledge, this is the first report that simultaneously compared the effects of bezafibrate and pravastatin on RLPs and LDL and HDL subclasses.
Both drugs significantly decreased RLP-C and RLP-TG levels, but RLP-C was reduced more effectively by pravastatin, while RLP-TG was by bezafibrate (Table 2, Fig. 1). Because
Acknowledgements
The authors would like to thank Dr Takamitsu Nakano (Japan Immunoresearch Laboratories) for measuring RLP-C and RLP-TG concentrations, Dr Abby R Saniabadi (Japan Immunoresearch Laboratories) for critical reading of the manuscript, and Dr Atsushi Araki, Dr Toshiyuki Horiuchi and Dr Tetsuro Nakamura (Tokyo Metropolitan Geriatric Hospital) for their support in recruiting the participants.
References (22)
- et al.
Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology
J. Lipid Res.
(1995) - et al.
Identification of multiple subclasses of plasma low density lipoproteins in normal humans
J. Lipid Res.
(1982) - et al.
Characterization of human high-density lipoproteins by gradient gel electrophoresis
Biochim. Biophys. Acta
(1981) - et al.
Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
J. Am. Coll. Cardiol.
(1998) - et al.
Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia
Atherosclerosis
(1994) - et al.
Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin
Atherosclerosis
(1998) - et al.
Effects of pravastatin on apolipoprotein-specific high density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia
Atherosclerosis
(1993) Lipoprotein physiology in non-diabetic and diabetic states: relationship to atherosclerosis
Diabetes Care
(1991)- et al.
Prospective study of small LDLs as a risk factor for type 2 diabetes in elderly men and women
Circulation
(1995) - et al.
LDL subclass phenotypes and the insulin resistance syndrome in women
Circulation
(1993)
Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients
Diabetes Care
Cited by (23)
Elevated Remnant Lipoprotein Related to Adverse Events in Patients with Chronic Limb-Threatening Ischemia after Endovascular Therapy for Below-the-Knee Lesions
2022, Annals of Vascular SurgeryCitation Excerpt :There are several medications that reduce serum remnant lipoprotein. The present and previous reports showed that fibrates and ezetimibe as well as statins effectively reduce RLP-C.33–36 However, whether such reduction improves prognosis of patients with CLTI remains to be seen. Preoperative serum remnant lipoprotein level was associated with prognosis of patients with CLTI who had received EVT for de novo below-the-knee lesions.
Serum cholesterol and triglyceride reference ranges of twenty lipoprotein subclasses for healthy Japanese men and women
2013, AtherosclerosisCitation Excerpt :In this study, we present data gathered by use of a standardized HPLC methodology that separates serum lipoproteins by size ranging from CM with a diameter of >80 nm to very small HDL with a diameter of 7.6 nm. This methodology has been pioneered by one of the co-authors (Dr. Okazaki), and has been utilized in many studies of both animals and humans [20,22,24]. The present study for the first time presents reference ranges based on a large population of healthy Japanese men and women, and it examines differences in the cholesterol and triglyceride content of 20 different lipoprotein subclasses, with further examination by menopausal status.
Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: A possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor: Atorvastatin and hepatic LRP1 expression
2011, Metabolism: Clinical and ExperimentalCitation Excerpt :Altogether, hepatic LRP1 and LDL receptor expression showed similar response to atorvastatin treatment. Although we did not measure the level of RLP-C in rat blood, HMG-CoA reductase inhibitors including atorvastatin have been shown to reduce plasma RLP-C in several clinical studies [18-24]. The known mechanism of remnant lipoprotein reduction by HMG-CoA reductase inhibitors involves up-regulation of the hepatic LDL receptor via SREBP-2 and decreased hepatic secretion of apolipoprotein B–containing lipoproteins.
Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets
2010, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids